Epigenetics: new tool for precision medicine

27 June 2016
On June 27, four new papers, co-published by several BLUEPRINT members and others in Nature Biotechnology and Nature Communications, mark the feasibility of epigenetic analysis for clinical diagnostics and precision medicine.

Epigenetic changes occur in all cancers, and in various other diseases. Measuring these changes provides unprecedented insights into the disease mechanisms at work in individual patients, which is important for better diagnosis and patient-specific treatment decisions

In this series of four papers, led by Christoph Bock (CeMM Research Center for Molecular Medicine of the Austrian Academy of Science Vienna) and Stephan Beck (University College London (UCL)), an international group of scientists have validated the feasibility of epigenetic analysis for clinical application.

The papers include:
* Quantitative comparison of DNA methylation assyas for biomarker development and clinical applications. C. Bock et al. Nature Biotechnology

* Saturation analysis for whole-genome bisulfite sequencing data. Libertini et al. Nature Biotechnology

* Information recovery from low coverage whole-genome bisulfite sequencing. Libertini et al. Nature Communication

* Chromatin Accessibility maps of chronic lymphocytic leukemia identify subtype-specific epigenome signatures and transcription regulatory networks. Rendeiro, Schmidl, Strefford et al. Nature Communication

Press releases are available from CeMM and UCL.